Evidence map›Paper›PMID 36422197›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Identification and Characterization of Novel Mutations in Chronic Kidney Disease (CKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Saudi Subjects by Whole-Exome Sequencing.

Othman R Alzahrani, Hanan E Alatwi, Amnah A Alharbi, Abdulrahman H Alessa, Osama M Al-Amer, Abeer F R Alanazi, Anwar M Shams, Esra'a Alomari, Abdallah Y Naser, Faisal A Alzahrani and 5 more

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Utility of Genetic Testing in Adults with CKD: A Systematic Review and Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Othman R AlzahraniDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0000-0002-2726-0473
Hanan E AlatwiDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Amnah A AlharbiGenome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0000-0001-9879-9508
Abdulrahman H AlessaDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Osama M Al-AmerGenome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Abeer F R AlanaziDepartment of Pharmaceutical and Biological Sciences, UCL School of Pharmacy, London WC1E 6BT, UK.
Anwar M ShamsDepartment of Pharmacology, College of Medicine, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0002-9888-2739
Esra'a AlomariDepartment of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan.ORCID 0000-0002-2130-9336
Abdallah Y NaserDepartment of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan.ORCID 0000-0001-8440-7446
Faisal A AlzahraniDepartment of Biochemistry, Faculty of science, Embryonic Stem Cell Unit, King Fahad Center for Medical Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-0441-4000
Salman HosawiDepartment of Biochemistry, Faculty of Science, King AbdulAziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-0639-1618
Saeed M AlghamdiDepartment of Medicine, King Faisal Specialist Hospital and Research Centre, P.O. Box 40047, Jeddah 21499, Saudi Arabia.ORCID 0000-0001-7790-0486
Wed A AbdaliResearch Center, King Faisal Specialist Hospital and Research Center, MBC J04, P.O. Box 40047, Jeddah 21499, Saudi Arabia.
Imadeldin ElfakiGenome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Yousef M HawsawiResearch Center, King Faisal Specialist Hospital and Research Center, MBC J04, P.O. Box 40047, Jeddah 21499, Saudi Arabia.ORCID 0000-0003-1901-697X
University of Tabuk · SAIsra University · JOKing Abdulaziz University · SAKing Faisal Specialist Hospital & Research Centre · SAAlfaisal University · SATaif University · SAUniversity College London · GB

Funding

King Abdulaziz City for Science Technology 2018-36University of Tabuk S-1441-0080
6 · The paper itself

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is a condition usually caused by a single gene mutation and manifested by both renal and extrarenal features, eventually leading to end-stage renal disease (ESRD) by the median age of 60 years worldwide. Approximately 89% of ADPKD patients had either PKD1 or PKD2 gene mutations. The majority (85%) of the mutations are in the PKD1 gene, especially in the context of family history. Objectives: This study investigated the genetic basis and the undiscovered genes that are involved in ADPKD development among the Saudi population. Materials and Methods: In this study, 11 patients with chronic kidney disease were enrolled. The diagnosis of ADPKD was based on history and diagnostic images: CT images include enlargement of renal outlines, renal echogenicity, and presence of multiple renal cysts with dilated collecting ducts, loss of corticomedullary differentiation, and changes in GFR and serum creatinine levels. Next-generation whole-exome sequencing was conducted using the Ion Torrent PGM platform. Results: Of the 11 Saudi patients diagnosed with chronic kidney disease (CKD) and ADPKD, the most common heterozygote nonsynonymous variant in the PKD1 gene was exon15: (c.4264G > A). Two missense mutations were identified with a PKD1 (c.1758A > C and c.9774T > G), and one patient had a PKD2 mutation (c.1445T > G). Three detected variants were novel, identified at PKD1 (c.1758A > C), PKD2L2 (c.1364A > T), and TSC2 (deletion of a’a at the 3’UTR, R1680C) genes. Other variants in PKD1L1 (c.3813_381 4delinsTG) and PKD1L2 (c.404C > T) were also detected. The median age of end-stage renal disease for ADPK patients in Saudi Arabia was 30 years. Conclusion: This study reported a common variant in the PKD1 gene in Saudi patients with typical ADPKD. We also reported (to our knowledge) for the first time two novel missense variants in PKD1 and PKD2L2 genes and one indel mutation at the 3’UTR of the TSC2 gene. This study establishes that the reported mutations in the affected genes resulted in ADPKD development in the Saudi population by a median age of 30. Nevertheless, future protein−protein interaction studies to investigate the influence of these mutations on PKD1 and PKD2 functions are required. Furthermore, large-scale population-based studies to verify these findings are recommended.

Indexed as

Kidney Failure, ChronicPolycystic Kidney, Autosomal DominantRenal Insufficiency, Chronic3' Untranslated RegionsAdultExome SequencingHumansMembrane ProteinsMutationSaudi ArabiaTRPP Cation Channels3' Untranslated RegionsMembrane ProteinsPKD1L1 protein, humanTRPP Cation Channelsautosomal dominant polycystic kidney disease (ADPKD)autosomal recessive polycystic kidney disease (ARPKD)end-stage renal disease ESRDPKD2polycystin-1-polycystin-2 PKD1whole-exome sequencing

Identifiers

PMID36422197
PMCPMC9692281
OpenAlexW4309606890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.